Roadshow
PCR-CE SMN/DMD kit
Our neuromuscular disease panel integrates SMA and DMD testing using a fluorescence PCR-capillary electrophoresis (PCR-CE) platform.
The SMA assay quantifies SMN1 and SMN2 exon 7/8 copy numbers within 3 hours, supporting accurate genotype classification and clinical decision-making. The DMD assay evaluates all 79 exons of the DMD gene to detect deletions or duplications, enabling comprehensive coverage for Duchenne and Becker muscular dystrophy. Both assays offer high sensitivity, full automation compatibility, and complete replacement of MLPA. Ideal for carrier screening, newborn testing, and early diagnosis of neuromuscular disorders.
- Established 2018
- Company Origin Biotechnology., Ltd.
- Telephone +886 02-3393-1118#12
- Email yuwei@oribio.com.tw
- Address 5F.-1, No. 12, Linsen S. Rd., Zhongzheng Dist., Taipei, Taiwan
Origin is an innovative biotechnology company based on autonomous research and development to the field of molecular diagnostics. Our business strategy aims to develop rapid, accurate IVD kit to fulfill unresolved clinical demands. Our mission focus on prevention, screening, and diagnose of gynecological, pediatric, and genetic disease. Origin have recently made significant breakthroughs in developing a comprehensive panel for genetic disease testing and a full-scope fragment analysis solution, offering an advanced alternative to the current CNV gold standard. Our product portfolio demonstrates outstanding performance in FXS, SMA, and Thalassemia testing in both specifications and coverage. Moreover, we offer the world’s first and only IVD assay for Kawasaki Disease, addressing an urgent unmet need in pediatric diagnostics.